Aqneursa in Jordan

Aqneursa - overview

Aqneursa (lusutrombopag) is manufactured by Shionogi (to verify exact US tradename) and indicated for Thrombocytopenia in CLD – oral suspension. It is a Levacetylleucine approved by the US FDA in 2024 and may be accessible to patients in Jordan through a Named Patient Program or personal-import pathway.

Access in Jordan

Jordan's JFDA operates a compassionate-use framework for unregistered drugs; requires physician and JFDA approval.

How Reserve Meds coordinates access in Jordan

1. Patient or treating physician submits a request.
2. We verify clinical appropriateness and Jordan-specific eligibility.
3. Treating physician in Jordan issues prescription and clinical justification.
4. Country-specific NPP/personal-import forms are prepared and filed.
5. We source Aqneursa from a DSCSA-compliant US specialty wholesaler.
6. Cold-chain shipment to the patient's physician or hospital pharmacy in Jordan.

Typical timeline for Jordan

End-to-end, most requests are completed in 2-6 weeks. Jordan's tier 2 regulatory maturity typically supports moderate processing times.

What patients and physicians in Jordan ask

• Is the pathway legal in Jordan? Yes - it operates under Jordan's established NPP or personal-import framework.
• Does my insurance cover it? Typically no for NPP drugs; patient prepayment is standard.
• What physician credentials do I need? A licensed physician in Jordan able to issue the prescription and clinical justification.
• What if the drug is in shortage? We will inform you upfront and decline rather than promise what we cannot deliver.
• Can I re-supply? Yes - for chronic therapies we arrange ongoing re-supply.

Start a request for Aqneursa in Jordan

Request Aqneursa